Bayer AG, of Leverkusen, Germany, said it inked a collaboration with the Population Health Research Institute and the Canadian Stroke Prevention Intervention Network to conduct the global phase III, indication-seeking trial, NAVIGATE ESUS, which will investigate the benefits of once-daily, oral factor Xa inhibitor rivaroxaban in patients with embolic stroke of undetermined source or cryptogenic stroke.